FAM45A Inhibitors
FAM45A inhibitors represent a chemical class designed to specifically target and hinder the activity of the FAM45A protein, a protein potentially involved in cellular processes. The exact biological functions of FAM45A are not clearly defined, but these inhibitors are developed based on the premise that FAM45A plays a role in particular intracellular signaling cascades or contributes to the regulation of gene expression within the cell. The inhibitors function by interfering with the protein's ability to interact with other molecules or by obstructing its active sites. This inhibition could result from direct binding to the FAM45A protein, altering its conformation and thus inactivating its function. Alternatively, these compounds might act indirectly, targeting upstream regulators or downstream effectors in the signaling pathways where FAM45A is a critical component. By doing so, they would effectively reduce the protein's activity, despite not interacting with the protein directly. These inhibitors are not merely nonspecific antagonists; rather, they are fine-tuned to affect pathways or processes that FAM45A is believed to influence.
The development of FAM45A inhibitors is a sophisticated process that takes into account the molecular makeup and the interaction network of the protein. The inhibitors are designed to be highly selective, possessing a high affinity for FAM45A or its associated pathways, ensuring minimal off-target effects on unrelated proteins or biological pathways. The specificity of these inhibitors hinges on their structural compatibility with FAM45A or elements within its regulatory network. By disrupting the normal functioning of FAM45A, these inhibitors could potentially alter various cellular processes that the protein is involved with, leading to a decrease in its functional activity. Although the precise pathways modulated by FAM45A have not been definitively elucidated, the inhibitors are constructed on the rationale that they would impede any process FAM45A is a part of, based on the known or predicted molecular interactions and regulatory roles that have been attributed to the protein from scientific investigations.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor that potentially leads to the inhibition of retinoblastoma (Rb) phosphorylation. The hypophosphorylated state of Rb restricts E2F target genes, which are essential for cell cycle progression. As FAM45A is proposed to be involved in cell cycle regulation, the inhibition of Rb phosphorylation by Palbociclib may consequently result in a decrease in FAM45A activity due to reduced transcriptional activation of its associated genes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK kinases. Inhibition of ROCK can lead to alterations in actin cytoskeleton dynamics. Since FAM45A might be involved in the regulation of cytoskeletal remodeling, the use of Y-27632 can indirectly lead to the inhibition of FAM45A's role in actin filament organization. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an AKT inhibitor. AKT pathway inhibition can lead to decreased cell survival and proliferation signals. If FAM45A functions downstream of or in conjunction with AKT signaling, inhibiting AKT with Triciribine could lead to decreased FAM45A-mediated cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, enzymes upstream of ERK1/2 in the MAPK pathway. By inhibiting MEK1/2, U0126 prevents the activation of ERK1/2, potentially reducing the activity of downstream proteins involved in cell cycle progression and survival, which may include FAM45A. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which prevents the phosphorylation and activation of PI3K downstream targets, including AKT. FAM45A, if functioning in the PI3K/AKT pathway, would have decreased activity due to the reduction in PI3K signaling, leading to potential inhibition of processes that FAM45A influences. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and by inhibiting mTOR signaling, it can decrease protein synthesis and cell proliferation. If FAM45A is involved in mTOR signaling pathways, its functional activity could be indirectly inhibited by Rapamycin due to decreased downstream signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in the regulation of apoptosis and cell proliferation. Inhibition of JNK may downregulate the activity of FAM45A if it is part of the JNK signaling cascade, thereby reducing its function in cellular processes that it regulates. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The inhibition of p38 MAPK can lead to decreased response to stress stimuli and cytokines. If FAM45A is functionally related to the p38 MAPK pathway, then SB203580 could indirectly inhibit its activity by reducing the pathway's signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that impedes the MAPK/ERK pathway. This inhibition can lead to reduced cell proliferation and differentiation signals, potentially affecting FAM45A's function if it is associated with this pathway, resulting in decreased activity of FAM45A. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor, and by blocking EGFR signaling, it can affect cell proliferation and survival pathways. If FAM45A acts downstream of EGFR, its activity could be indirectly reduced by Gefitinib through the inhibition of EGFR signaling. | ||||||